Croatia’s GlycanAge secures €3.9M from LAUNCHub and Kadmos Capital

Croatian-founded and UK-based biotech longevity startup GlycanAge has secured €3.9 million in a round led by LAUNCHub Ventures and Kadmos Capital. The fresh capital will be instrumental in the strategic shift from the longevity space to the broader diagnostics market, EU-Startups reports.

About GlycanAge

  • GlycanAge was founded in 2020 with the aim to commercialize the 20-year glycobiology experience of its co-founder Nikolina Lauc. The startup offers a cutting-edge biological age test that utilizes glycan biomarkers to enable early health risks prevention strategies for both consumers and healthcare professionals.
  • The startup is based on the Human Glycome research project, which studies the critical role of glycans in the body’s biological functions, which may undergo changes in over 70 diseases. In some cases, studying these biomarkers can reveal vulnerability to certain diseases a decade prior to symptoms and diagnosis. 

We are thrilled to have the support of LAUNCHub Ventures and Kadmos Capital, who share our vision for a healthier future. This funding round marks a significant milestone for GlycanAge, and we are excited to continue our journey towards transforming healthcare and empowering individuals to take control of their well-being,

Nikolina Lauc, CEO of GlycanAge, commented.

Who are the investors?

The €3.9 million funding round was co-led by LAUNCHub Ventures and Kadmos Capital. This endeavor was aided by significant grant support, including a $140,000 grant from Mubadala’s accelerator program HUB71, and an additional $220,000 from an EU AI grant.

  • LAUNCHub Ventures is a Sofia-based early-stage VC fund, supporting technology startups in the Seed and Series A funding stages across SEE and CEE. Its initial investments are between €300,000 and €2 million, leading investment rounds up to €4 million. Also, the fund oftentimes continue supporting the funding needs of its portfolio companies in future rounds.
LAUNCHub Ventures recently made several investments, including in Colossyan, Sessions, and Transmetrics.
  • Kadmos Capital is a London-based Venture Capital Firm, focused on early stage investments in deep tech and impactful technologies.

Further plans

The fresh capital injection will help GlycanAge fuel the strategic shift from the longevity space to the broader diagnostics market. The funding will enable the company to establish a clear regulatory strategy and product pipeline.